Marker Therapeutics' Merger

Marker Therapeutics raised a round of funding on May 15, 2018. Investors include TapImmune.

Marker Therapeutics is dedicated to commercializing T cell therapies intended to eradicate liquid and solid tumors.…

Articles about Marker Therapeutics' Merger: